

Dietrich W Beelen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/24045/dietrich-w-beelen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

181
papers

4,936
citations

37
h-index

64
g-index

191
ext. papers

6,210
ext. citations

5.4
avg, IF

4.92
L-index

#	Paper	IF	Citations
181	Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.. <i>Cancer Medicine</i> , 2022 ,	4.8	1
180	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 3084-3087	4.4	
179	Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG. <i>Blood Advances</i> , 2021 ,	7.8	1
178	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021 , 96, 1186-1194	7.1	1
177	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). <i>Journal of Clinical Oncology</i> , 2021 , 39, 3318-3327	2.2	7
176	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021 , 35, 215-224	10.7	15
175	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2021 , 56, 605-613	4.4	2
174	Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM. <i>Blood</i> , 2021 , 137, 923-928	2.2	7
173	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT. <i>Leukemia and Lymphoma</i> , 2021 , 62, 399-409	1.9	0
172	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021 , 96, 69-79	7.1	11
171	Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 95.e1-95.e4		4
170	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1190-1199	4.4	5
169	The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT).	7.1	1
168	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 481-491	4.4	0
167	Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution. <i>American Journal of Hematology</i> , 2021 , 96, 436-445	7.1	4
166	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2021 , 195, 417-428	4.5	2
165	Veno-Venous Extracorporeal Membrane Oxygenation in Adult Patients with Sickle Cell Disease and Acute Chest Syndrome: a Single-Center Experience. <i>Hemoglobin</i> , 2020 , 44, 71-77	0.6	1

164	Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2365-2374	1.9	1
163	Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation. <i>Haematologica</i> , 2020 , 105, 1454-1464	6.6	1
162	Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020 , 190, 437-441	4.5	3
161	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020 , 10, 26	7	14
160	Fertility preservation and fulfillment of parenthood after treatment of hematological malignancies: results from the Aftercare in Blood Cancer SurvivorsP(ABC) study. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 1187-1194	4.2	2
159	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , 2020 , 189, 920-925	4.5	10
158	External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. <i>Blood</i> , 2020 , 135, 1386-1395	2.2	15
157	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1114-1125	4.4	28
156	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2335-2338	4.4	1
155	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e202-210	14.6	40
154	Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies. <i>American Journal of Transplantation</i> , 2020 , 20, 677-688	8.7	3
153	Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020 , 188, 428-437	4.5	5
152	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2020 , 95, 282-294	7.1	3
151	Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1642-1646	4.4	3
150	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , 2020 , 26, 6475-6482	12.9	9
149	Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation. <i>Cancers</i> , 2020 , 12,	6.6	2
148	Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. <i>Bone Marrow Transplantation</i> , 2020 , 55, 224-232	4.4	5
147	Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020 , 105, 1723-1730	6.6	7

146	EASIX and mortality after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 553-561	4.4	23
145	Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020 , 55, 595-602	4.4	9
144	Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allograft: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 451-457	4.7	8
143	Allogeneic transplantation of peripheral blood stem cell grafts results in a massive decrease of primitive hematopoietic progenitor frequencies in reconstituted bone marrows. <i>Bone Marrow Transplantation</i> , 2020 , 55, 100-109	4.4	1
142	Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020 , 189, e213-e217	4.5	7
141	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 108	22.4	33
140	Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. <i>European Journal of Haematology</i> , 2019 , 103, 552-557	3.8	8
139	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019 , 104, 929-936	6.6	12
138	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1975-1983	4.7	32
137	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2019 , 186, 767-776	4.5	10
136	Individual Immune-Modulatory Capabilities of MSC-Derived Extracellular Vesicle (EV) Preparations and Recipient-Dependent Responsiveness. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
135	Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Journal of Hematology and Oncology</i> , 2019 , 12, 108	22.4	14
134	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2404-2414	1.9	8
133	Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. <i>British Journal of Haematology</i> , 2019 , 185, 725-732	4.5	7
132	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019 , 25, 603-611	50.5	136
131	Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1499-1510	4.4	15
130	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Haematologica</i> , 2019 , 104, 1782-1788	6.6	26
129	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. <i>Blood</i> , 2019 , 133, 2233-2242	2.2	60

128	Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival. <i>Frontiers in Immunology</i> , 2019 , 10, 3027	8.4	5
127	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2251-2260	4.7	10
126	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 68	22.4	9
125	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2167-2171	4.7	35
124	Ileostomy for steroid-resistant acute graft-versus-host disease of the gastrointestinal tract. <i>Annals of Hematology</i> , 2019 , 98, 2407-2419	3	3
123	Comparison of a New Reduced Toxicity Myeloablative Treosulfan and Fludarabine Preparative Regimen with Myeloablative Busulfan or Melphalan in Combination with Fludarabine in Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes: A Retrospective Matched Cohort Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1147-1155	2.2	1
122	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019 , 134, 45-45	2.2	
121	Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study. <i>EBioMedicine</i> , 2019 , 49, 202-212	8.8	7
120	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 686-695	10.7	14
119	Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. <i>American Journal of Hematology</i> , 2019 , 94, 431-438	7.1	9
118	Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients. <i>Annals of Hematology</i> , 2019 , 98, 491-500	3	5
117	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e128-e140	4.7	24
116	Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. <i>American Journal of Hematology</i> , 2019 , 94, 80-86	7.1	12
115	Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation. <i>Haematologica</i> , 2019 , 104, 827-834	6.6	3
114	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. <i>Haematologica</i> , 2019 , 104, 955-962	6.6	12
113	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1001-1009	4.4	17
112	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018 , 124, 2134-2141	6.4	19
111	High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2018 , 180, 840-853	4.5	9

110	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2018 , 96, 73-81	7.5	24
109	Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1173-1183	4.9	3
108	Microbiologic Diagnostic Workup of Acute Respiratory Failure with Pulmonary Infiltrates after Allogeneic Hematopoietic Stem Cell Transplantation: Findings in the Era of Molecular- and Biomarker-Based Assays. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1707-1714	4.7	10
107	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018 , 24, 282-291	50.5	144
106	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018 , 53, 255-263	4.4	8
105	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1406-1414	4.7	28
104	Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantIFERON-CMV-assay and real time PCR. <i>Journal of Clinical Virology</i> , 2018 , 99-100, 61-66	14.5	15
103	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haematopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , 2018 , 4, 114-123	14.6	42
102	Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1188-1192	4.4	5
101	Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1149-1156	4.4	6
100	Sensitive detection of rare antigen-specific T cells directed against WilmsPtumor 1 by FluoroSpot assay. <i>Leukemia and Lymphoma</i> , 2018 , 59, 490-492	1.9	
99	Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2558-2567	4.7	24
98	Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1351-1355	4.4	9
97	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1406-1414	4.7	28
96	Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. <i>Haematologica</i> , 2018 , 103, 1527-1534	6.6	3
95	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 507-513	4.7	5
94	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2018 , 103, 237-245	6.6	42
93	Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2018 , 9, 2236	8.4	9

92	Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. <i>Leukemia</i> , 2018 , 32, 2558-2571	10.7	11
91	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , 2018 , 2, 2127-2135	7.8	24
90	Clinical Utility of Quantitative PCR for Chimerism and Engraftment Monitoring after Allogeneic Stem Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1658-1668	4.7	22
89	Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow	7.1	21
88	Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia: A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 667-675.e2	2	9
87	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2017 , 178, 521-533	4.5	21
86	Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2017 , 123, 2671-2679	6.4	25
85	Intestinal T lymphocyte homing is associated with gastric emptying and epithelial barrier function in critically ill: a prospective observational study. <i>Critical Care</i> , 2017 , 21, 70	10.8	15
84	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017 , 102, 139-149	6.6	65
83	Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3143-3152	2.2	20
82	A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT. <i>Blood</i> , 2017 , 130, 1270-1273	2.2	20
81	Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 822-833	1.9	16
80	Allogeneic Stem Cell Transplantation for Patients Age \geq 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 44-52	4.7	36
79	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. <i>Blood Advances</i> , 2017 , 1, 669-680	7.8	30
78	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 25	22.4	44
77	Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. <i>European Journal of Cancer</i> , 2016 , 62, 1-8	7.5	21
76	HLA mismatching as a strategy to reduce relapse after alternative donor transplantation. <i>Seminars in Hematology</i> , 2016 , 53, 57-64	4	37
75	The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	21

74	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 89	22.4	24
73	Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016 , 101, 241-7	6.6	4
72	Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. <i>Oncologist</i> , 2016 , 21, 377-83	5.7	7
71	Endoscopic and Histological Findings Are Predicted by Fecal Calprotectin in Acute Intestinal Graft-Versus-Host-Disease. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 2019-26	4	8
70	CD34+ highly enriched allogeneic stem cell transplantation in a patient with mixed phenotype acute leukemia and <i>Fusarium solani</i> sepsis. <i>Annals of Hematology</i> , 2016 , 95, 155-156	3	2
69	Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT. <i>Blood</i> , 2016 , 128, 120-9	2.2	28
68	Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>European Journal of Haematology</i> , 2015 , 96, 90-7	3.8	15
67	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2015 , 100, 203-11	6.6	41
66	Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. <i>Haematologica</i> , 2015 , 100, 696-702	6.6	105
65	Methylenetetrahydrofolate reductase polymorphism has no differential effect on the outcome of allogeneic hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2473-5	1.9	1
64	T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. <i>Haematologica</i> , 2015 , 100, 558-64	6.6	25
63	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015 , 171, 222-217	4.5	54
62	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. <i>Blood</i> , 2015 , 125, 3347-50; quiz 3364	2.2	114
61	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. <i>Lancet Haematology</i> , 2015 , 2, e384-92	14.6	33
60	Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Leukemia Research</i> , 2015 , 39, 933-7	2.7	18
59	Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions—a retrospective multicenter analysis from the German Cooperative Transplant Study Group. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 653-60	4.7	125
58	Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 288-96	2.2	73
57	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1367-81	4.9	5

56	Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 279-81	4.7	61
55	Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma. <i>Molecular and Clinical Oncology</i> , 2014 , 2, 773-782	1.6	3
54	Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T-cell lymphoma - a case series of the ADF working group "cutaneous lymphomas". <i>JDDG - Journal of the German Society of Dermatology</i> , 2014 , 12, 39-46	1.2	2
53	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. <i>Haematologica</i> , 2014	6.6	23
52	Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. <i>Transplant International</i> , 2014 , 27, 77-86	3	107
51	Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?. <i>Transplantation</i> , 2014 , 98, 569-77	1.8	8
50	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014 , 124, 1216-1216	2.2	
49	Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3259-71	2.2	101
48	Maternal molecular features and gene profiling of monocytes during first trimester pregnancy. <i>Journal of Reproductive Immunology</i> , 2013 , 99, 62-8	4.2	7
47	Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. <i>Psycho-Oncology</i> , 2013 , 22, 1509-16	3.9	61
46	Allogeneic haematopoietic stem cell transplantation in a patient with cutaneous α T-cell lymphoma. <i>Acta Dermato-Venereologica</i> , 2013 , 93, 360-1	2.2	11
45	Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2013 , 121, 440-6	2.2	110
44	CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2013 , 122, 3359-64	2.2	149
43	Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2013 , 98, 1004-9	6.6	14
42	Response: T cells are required for the CMV-induced antileukemia effect after transplant. <i>Blood</i> , 2012 , 119, 1090-1091	2.2	16
41	Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1415-21	4.7	71
40	Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. <i>Blood</i> , 2012 , 120, 2521-8	2.2	49
39	Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Haematologica</i> , 2012 , 97, 1574-81	6.6	54

38	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1035-44	21.7	190
37	Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. <i>Haematologica</i> , 2012 , 97, e34-5	6.6	58
36	Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. <i>Haematologica</i> , 2012 , 97, 1523-31	6.6	100
35	Influence of Micrnas Expression in Graft-Versus-Host Disease After Allogeneic Transplantation.. <i>Blood</i> , 2012 , 120, 3062-3062	2.2	
34	Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. <i>Blood</i> , 2011 , 118, 1402-12	2.2	242
33	Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. <i>Haematologica</i> , 2011 , 96, 972-9	6.6	49
32	Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. <i>British Journal of Haematology</i> , 2011 , 152, 713-20	4.5	41
31	H1N1 in allogeneic stem cell recipients: courses of infection and influence of vaccination on graft-versus-host-disease (GVHD). <i>Annals of Hematology</i> , 2011 , 90, 117-8	3	12
30	Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. <i>Haematologica</i> , 2011 , 96, 1344-50	6.6	47
29	Modulating impact of human chorionic gonadotropin hormone on the maturation and function of hematopoietic cells. <i>Journal of Leukocyte Biology</i> , 2011 , 90, 1017-26	6.5	18
28	Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011 , 118, 4106-4106	2.2	
27	Inhibition of mTOR with Everolimus (RAD001) and Silencing by Vascular Endothelial Cell Growth Factor Specific siRNA Induces Additive Antitumor Activity in Multiple Myeloma Cells,. <i>Blood</i> , 2011 , 118, 3984-3984	2.2	
26	Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 405-11	2.2	238
25	Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1649-57	4.7	14
24	Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. <i>Blood</i> , 2010 , 116, 2438-47	2.2	240
23	Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. <i>Haematologica</i> , 2010 , 95, 388-97	6.6	18
22	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. <i>Blood</i> , 2010 , 115, 1880-5	2.2	158
21	Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. <i>Blood</i> , 2010 , 116, 122-8	2.2	31

20	No influence of gene polymorphism of LCT (C13910T) on transplantation outcomes in acute myeloid leukemia patients who received transplantations from HLA-identical sibling donors. <i>Blood</i> , 2010 , 115, 3644-5; author reply 3645-6	2.2	
19	Toll-Like-Receptor Expression and Cellular Immune Reconstitution In AML-Patients with Elevated Serum Ferritin Levels After Allogeneic transplant.. <i>Blood</i> , 2010 , 116, 1049-1049	2.2	2
18	Treosulfan, Etoposide and Cyclophosphamide as Non TBI-Conditioning Regimen Followed by Allogeneic SCT for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010 , 116, 1327-1327	2.2	1
17	Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial. <i>Blood</i> , 2010 , 116, 2357-2357	2.2	1
16	A Cytomegalovirus Reactivation Is Associated with An Improved Progression-Free Survival Rate In Patients with Lymphoma After Allogeneic Transplant. <i>Blood</i> , 2010 , 116, 4912-4912	2.2	
15	Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis. <i>Blood</i> , 2010 , 116, 3500-3500	2.2	
14	The Impact of Donor Type In Patients with AML and High Risk Cytogenetic Aberrations. <i>Blood</i> , 2010 , 116, 2369-2369	2.2	
13	Additive Effects of Anti-Leukemia Capacity by Gfi-1B- and Bcr-Abl-Specific siRNA In Advanced Chronic Myeloid Leukemic Cells. <i>Blood</i> , 2010 , 116, 4466-4466	2.2	
12	Monosomal Karyotype Predicts Survival In Patients with High Risk AML Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010 , 116, 2748-2748	2.2	
11	Incidence and Outcome of Auto/Alloimmune Hepatitis with Hepatic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010 , 116, 4534-4534	2.2	
10	Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. <i>Haematologica</i> , 2009 , 94, 141-4	6.6	58
9	The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004. <i>Annals of Hematology</i> , 2009 , 88, 1237-1247	2.2	21
8	Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. <i>Haematologica</i> , 2009 , 94, 542-9	6.6	83
7	Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. <i>Blood</i> , 2009 , 113, 3903-10	2.2	47
6	Genetic Polymorphism of NAD(P)H:Quinine Oxidoreductase 1 Is Associated with An Increased Treatment-Related Mortality in Patients Undergoing Allogeneic Transplantation.. <i>Blood</i> , 2009 , 114, 3342-3342	2.2	
5	Matched Unrelated Donor Allogeneic Stem Cell Transplantation in High Risk Acute Lymphoblastic Leukemia (ALL) After a Preparative Regimen of Hyperfractionated Total Body Irradiation and High-Dose Etoposide [A Feasibility Study within the German Multicenter Study Group for Adult ALL.. <i>Blood</i> , 2009 , 114, 3389-3389	2.2	
4	Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. <i>Oncology Research and Treatment</i> , 2008 , 31, 691-3	2.8	11
3	Therapeutic Application of Small Interfering RNA Directed Against bcr-abl Transcripts to a Patient with Imatinib-Resistant Chronic Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 4581-4581	2.2	

2	Impact of Cytogenetics on Outcome of Patients with MDS or Secondary AML Undergoing Allogeneic HSCT from HLA-Identical Siblings: A Retrospective Analysis of the EBMT-CLWP.. <i>Blood</i> , 2006 , 108, 2653-2653	2.2	4
1	Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation. <i>Transplantation</i> , 1990 , 50, 421-7	1.8	27